EDITORIAL SECTION

Articles

Biopharma M&A and Licensing: Strategic Partnerships Fueling Innovation

For much of the last decade acquisitions and licensing agreements were debated in European boardrooms as rival answers to the same question how to refill a pipeline faster than internal research alone allows That framing no longer holds In the most effective pharmaceutical companies run both instruments in parallel choosing between them asset by asset according to scientific maturity geographic o...

Strategic Synthesis: Shift to Continuous Manufacturing in Pharmaceuticals

The pharmaceutical industry is at a decisive inflection point necessitated by a move away from legacy batch processing toward Continuous Manufacturing CM This transition is no longer a peripheral innovation but a core strategic imperative for organizations seeking to maintain global competitiveness and uphold the highest standards

The Growing Role of Real-World Evidence in European Drug Development

For decades the randomised controlled trial has been the gold standard of pharmaceutical evidence in Europe and it still is Yet the evidence that shapes a medicines journey from laboratory to patient is no longer confined to the controlled world of the trial protocol Electronic health records disease registries insurance claims biobanks and patientreported data are now being mobilised at continent...

Digital Twins in Pharmaceutical R&D: Simulating Biology for Faster Innovation

For most of its modern history pharmaceutical research has been an experimental science with a statistical conscience Build the molecule dose the animal run the trial count the failures and let the survivors pay for everything that did not make it That arrangement has become progressively harder to defend Attrition remains concentrated in the phases where money has already

Building Patient-Centric Clinical Trials: Technologies, Strategies, and Regulatory Considerations

Patientcentricity in clinical trials represents a crucial cultural and operational transformation in the development and evaluation of new treatments The patient experience has evolved from a secondary consideration to a central priority in trial design driven by

Adapting to the Changing Landscape of Clinical Trials in Europe

Clinical trials constitute the backbone of medical research driving innovation and shaping the landscape of healthcare Over the years Europe has experienced a profound transformation in its approach to clinical trials

Techno Trends

Alume Biosciences Secures FDA Breakthrough Therapy Designation for Bevonescein

Alume Biosciences has received Breakthrough Therapy Designation BTD from the US Food and Drug Administration FDA for bevonescein an investigational fluorescent drug being developed to support realtime nerve visualisation during head and neck surgery in adults Bevonescein is an intravenous fluorescent peptidedye conjugate that binds to nerve tissue

Projects

SK pharmteco Plans More Than US$200 Million Investment in Small Molecule and Peptide Manufacturing

SK pharmteco is planning a fiveyear investment of more than US million to expand and modernise its pharmaceutical development and manufacturing operations in the United States The programme will strengthen capabilities for small molecules and peptides while supporting a more

Research Insights

A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG

PIGACDG is a congenital disorder of glycosylation caused by pathogenic partial lossoffunction variants in the PIGA gene PIGA encodes an enzyme responsible for the catalytic transfer of Nacetylglucosamine

whitepaper

Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact

For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys